Effects of SSRIs on sexual function: A critical review

Journal of Clinical Psychopharmacology

Volumn 19, Issue 1, 1999, Pages 67-85

  Rosen, Raymond C ^a   Lane, Roger M ^b   Menza, Matthew ^a  

^a RUTGERS ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

^b PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 2 ADRENERGIC RECEPTOR BLOCKING AGENT; AMFEBUTAMONE; BUSPIRONE; CITALOPRAM; CLOMIPRAMINE; DOPAMINE RECEPTOR STIMULATING AGENT; FLUVOXAMINE; GINKGO BILOBA EXTRACT; PAROXETINE; SEROTONIN ANTAGONIST; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; SILDENAFIL;

DEPRESSION; DRUG SAFETY; FEMALE SEXUAL DYSFUNCTION; HUMAN; MALE SEXUAL DYSFUNCTION; PREMATURE EJACULATION; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; SEXUAL BEHAVIOR;

CLINICAL TRIALS; EJACULATION; FEMALE; HUMANS; IMPOTENCE; MALE; ORGASM; SEROTONIN UPTAKE INHIBITORS; SEXUALITY;

EID: 0032958811     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004714-199902000-00013     Document Type: Review

References (255)

1. Mathew RJ, Weinman M, Claghorn JL. Tricyclic side effects without tricyclics in depression. Psychopharmacol Bull 1980;16:53-60.
2. Nofzinger EA, Thase ME, Reynolds CF, Frank E, Jennings JR, Garamoni GL, Kupfer DJ. Sexual function in depressed men: assessment by self-report, behavioral, and nocturnal penile tumescence measures before and after treatment with cognitive behavior therapy. Arch Gen Psychiatry 1993;50:24-30.
3. Thase ME, Reynolds CF, Jennings JR, Frank E, Howell JR, Hauck PR, Berman S, Kupfer DJ. Nocturnal penile tumescence is diminished in depressed men. Biol Psychiatry 1988;24:33-46.
4. Clayton AH, McGarvey E, Clavet GJ, Piazza L. Assessment of sexual functioning in clinical and non-clinical populations. Poster presented at the 37th Annual New Clinical Drug Evaluation Unit Meeting, Boca Raton, FL, May 27-30, 1997.
5. Rosen RC. Alcohol and drug effects on sexual response: human experimental and clinical studies. Ann Rev Sex Res 1991;2: 119-79.
6. Segraves RT. Treatment-emergent sexual dysfunction in affective disorder: a review and management strategies. J Clin Psychiatry Monogr 1993;11:57-60.
7. Harvey KV, Balon R. Clinical implications of antidepressant drug effects on sexual dysfunction. Ann Clin Psychiatry 1995;7: 189-201.
8. Gitlin MJ. Psychotropic medications and their effects on sexual function: diagnosis, biology, and treatment approaches. J Clin Psychiatry 1994;55:406-13.
9. Segraves RT. Antidepressant-induced sexual dysfunction. J Clin Psychiatry 1998;59[suppl 4]:48-54.
10. Goldstein BJ, Goodnick PJ. Selective serotonin reuptake inhibitors in the treatment of affective disorders, III. Tolerability, safety and pharmacoeconomics. J Psychopharmacol 1998;12 [suppl B]:S55-S87.
11. Balon R, Yeragani VK, Pohl R, Ramesh C. Sexual dysfunction during antidepressant treatment. J Clin Psychiatry 1993;54: 209-12.
12. Lane RM. A critical review of SSRI-related sexual dysfunction, incidence, possible aetiology and implications for management. J Psychopharmacol 1997;11:72-82.
13. Baier D, Philipp M. Effects of antidepressants on sexual function. Fortschr Neurol Psychiatr 1994;62:14-21.
14. Herman JB, Brotman AW, Pollack MH, Falk WE, Biederman J, Rosenbaum JF. Fluoxetine-induced sexual dysfunction. J Clin Psychiatry 1990;51:25-7.
15. Zajecka J, Fawcett J, Schaff M, Jeffries H, Guy C. The role of serotonin in sexual dysfunction: fluoxetine-associated orgasm dysfunction. J Clin Psychiatry 1991;52:66-8.
16. Jacobsen FM. Fluoxetine-induced sexual dysfunction and an open trial of yohimbine. J Clin Psychiatry 1992;53:119-22.
17. Harrison WM, Rabkin JG, Ehrhardt AA, Stewart JW, McGrath PJ, Ross D, Quitkin FM. Effects of antidepressant medication on sexual function: a controlled study. J Clin Psychopharmacol 1986; 6:144-9.
18. Monteiro WO, Noshirvani HF, Marks IM, Lelliott PT. Anorgasmia from clomipramine in obsessive-compulsive disorder: a controlled trial. Br J Psychiatry 1987;151:107-12.
19. Bisserbe JC, Lane RM, Flament M, and the Franco-Belgian OCD Study Group. A double-blind parallel comparison of sertraline and clomipramine in outpatients with obsessive-compulsive disorder. Eur Psychiatry 1997;12:82-93.
20. Lepine JP, Wiseman R. Treatment of severe major depression: a double-blind study of sertraline and clomipramine. Eur Neuropsychopharmacol 1996;6:123.
21. Pigott TA, Pato MT, Bernstein SE, Grover GN, Hill JL, Tolliver TJ, Murphy DL. Controlled comparisons of clomipramine and fluoxetine in the treatment of obsessive-compulsive disorder. Arch Gen Psychiatry 1990;47:926-32.
22. Freeman PL, Trimble MR, Deakin JF, Stokes TM, Ashford JJ. Fluvoxamine versus clomipramine in the treatment of obsessive-compulsive disorder: a multicenter, randomized, double-blind, parallel group comparison. J Clin Psychiatry 1994;55:301-5.
23. Smeraldi E, Erzegovesi S, Bianchi I. Fluvoxamine vs. clomipramine treatment in obsessive-compulsive disorder: a preliminary study. New Trends Exper Clin Psychiatry 1992;8:63-5.
24. Wade AG, Lepola U, Koponen HJ, Pedersen V, Pedersen T. The effect of citalopram in panic disorder. Br J Psychiatry 1997;170: 549-53.
25. Ravindran AV, Judge R, Hunter BN, and the Paroxetine Study Group. A double-blind multicenter study in primary care comparing paroxetine and clomipramine in patients with depression and associated anxiety. J Clin Psychiatry 1997;58:112-8.
26. Lecrubier Y, Bakker A, Dunbar G, Judge R, and the Collaborative Paroxetine Panic Study Investigators. A comparison of paroxetine, clomipramine and placebo in the treatment of panic disorder. Acta Psychiatr Scand 1997;95:145-52.
27. Montejo-Gonzalez AL, Llorca G, Izquierdo JA, Ledesma A, Bousono M, Calcedo A, Carrasco JL, Ciudad J, Daniel E, De La Gandara J, Derecho J, Franco M, Gomez MJ, Macias JA, Martin T, Perez V, Sanchez JM, Sanchez JM, Vicens E. SSRI-induced sexual dysfunction: fluoxetine, paroxetine, sertraline, and fluvoxamine in a prospective, multicenter, and descriptive clinical study of 344 patients. J Sex Marital Ther 1997;23:176-94.
28. Zajecka J, Mitchell S, Fawcett J. Treatment-emergent changes in sexual function with selective serotonin reuptake inhibitors as measured with the Rush Sexual Inventory. Psychopharmacol Bull 1997;33:755-60.
29. Labbate LA, Grimes J, Hines A, Arana GW. Serotonin reuptake effects on sexual function induced in patients with anxiety disorders. Biol Psychiatry 1998;43:904-7.
30. Wise TN. A model for the assessment of sexual dysfunction etiology. J Clin Psychiatry Monogr 1994a;1:19-25.
31. Clayton AH, Owens JE, McGarvey EL. Assessment of paroxetine induced sexual dysfunction using the Changes in Sexual Functioning Questionnaire. Psychopharmacol Bull 1995;31: 397-413.
32. Clayton AH, McGarvey EL, Clavet GJ, Piazza L. Comparison of sexual functioning in clinical and non-clinical populations using the Changes in Sexual Functioning Questionnaire (CSFQ). Psychopharmacol Bull 1997;33:747-53.
33. Piazza LA, Markowitz JC, Kocsis JH, Leon AC, Miller NL, Adler D. Sexual functioning in chronically depressed patients treated with SSRI antidepressants: a pilot study. Am J Psychiatry 1997;154: 1757-9.
34. McGahuey CA, Gelenberg AJ, Laukes CA, Manber P, McKnight KM, Moreno FA, Delgado PL. The Arizona Sexual Experience Scale: validity and reliability. New Research Program and Abstracts, 150th Annual Meeting of the American Psychiatric Association, Washington, DC, 1997:116.
35. Reynolds CF, Frank E, Thase ME, Houck PR, Jennings JR, Howell JR, Lilienfeld SO, and Kupfer DJ. Assessment of sexual function in depressed, impotent, and healthy men: factor analysis of a brief sexual function questionnaire for men. Psychiatry Res 1993; 24:231-50.
36. Derogatis LR, Melisaratos N. The DSFI: a multidimensional measure of sexual functioning. J Sex Marital Ther 1979;5:244-81.
37. Crenshaw TL, Goldberg JP, eds. Sexual pharmacology: drugs that affect sexual functioning. New York: W.W. Norton & Company, 1996:285-306.
38. Laumann EO, Gagnon JH, Michael RT, Michaels S. The social organization of sexuality. Chicago: University Chicago Press, 1994.
39. Cassidy WL, Flanagan NB, Spellman M, Cohen ME. Clinical observations in manic-depressive disease: a quantitative study of 100 manic-depressive patients and 50 medically sick controls. JAMA 1957;164:1535-6.
40. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960;12:56-62.
41. Nelson JC, Charney DS. The symptoms of major depressive illness. Am J Psychiatry 1981;138:1-13.
42. Casper RC, Redmond E, Katz MM, Schaffer CB, Davis JM, Koslow SH. Somatic symptoms in primary affective disorders: presence and relationship to the classification of depression. Arch Gen Psychiatry 1985;42:1098-104.
43. Kivela SL, Pahkala K. Symptoms of depression in old people in Finland. Z Gerontol 1988;21:257-63.
44. Aldrich AP, Cook MD, Pedersen LR. Retrospective review of selective serotonin reuptake inhibitors-induced libido disturbance in women. Clin Drug Invest 1996;11:353-9.
45. Bradford J. An open pilot study of sertraline in the treatment of outpatients with pedophilia. Poster presented at the 148th annual meeting of the American Psychiatric Association, Miami, FL, May 20-25, 1995.
46. Kafka MP. Sertraline pharmacotherapy for paraphilias and paraphilia-related disorders: an open trial. Ann Clin Psychiatry 1994;6: 189-95.
47. Schwartz V. On a biological regulation of aggression [letter]. Am J Psychiatry 1995;152:1698-9.
48. Carek DJ. SSRI and sexual functioning [letter]. J Am Acad Child Adolesc Psychiatry 1996;35:1106-7.
49. Elmore JL, Quattlebaum JT. Female sexual stimulation during antidepressant treatment. Pharmacol Ther 1997;17:612-6.
50. Ahmad S. Paroxetine-induced priapism [letter]. Arch Intern Med 1995;155:645.
51. Mendelson WB, Franko T. Priapism with sertraline and lithium. J Clin Psychopharmacol 1994;14:434-5.
52. Swenson JR. Fluoxetine and sexual dysfunction [letter]. Can J Psychiatry 1993;38:297.
53. Murray MJ, Hooberman D. Fluoxetine and prolonged erection [letter]. Am J Psychiatry 1993;8:150:167-8.
54. Blashko CA. A double-blind, placebo-controlled study of sertraline in the treatment of outpatients with seasonal affective disorder. Eur Neuropsychopharmacol 1995;5:258.
55. Berk M, Acton M. Citalopram-associated clitoral priapism: a case series. Int J Psychopharmacol 1997;12:121-2.
56. Morris PL. Fluoxetine and orgasmic sexual experiences. Int J Psychiatry Med 1991;4:379-82.
57. Garcia-Campayo J, Sanz-Carrillo C, Lobo A. Orgasmic sexual experiences as a side effect of fluoxetine: a case report. Acta Psychiatr Scand 1995;91:69-70.
58. McLean JD, Forsythe RG, Kapkin IA. Unusual side effects of clomipramine associated with yawning. Can J Psychiatry 1983;28: 569-70.
59. Modell JG. Repeated observations of yawning, clitoral engorgement and orgasm associated with fluoxetine administration [letter]. J Clin Psychopharmacol 1989;9:63-5.
60. Bartlick BD, Kaplan P, Kaplan HS. Psychostimulants apparently reverse sexual dysfunction secondary to selective serotonin reuptake inhibitors. J Sex Marital Ther 1995;21:264-71.
61. Ellison JM. Exercise-induced orgasms associated with fluoxetine treatment of depression. J Clin Psychiatry 1996;57:596-7.
62. Montorsi F, Guazonni G, Rigatti P, Pozza G. Pharmacological management of erectile dysfunction. Drugs 1995;50:465-79.
63. Cavallini G. Fluoxetine in the treatment of psychogenic impotence secondary to premature ejaculation [abstract]. Eur Urol 1996;30[suppl 2]:840.
64. Power-Smith P. Beneficial sexual side-effects from fluoxetine. Br J Psychol 1994;164:249-50.
65. Smith DM, Levitte SS. Association of fluoxetine and return of sexual potency in three elderly men. J Clin Psychiatry 1993;54: 317-9.
66. Mendels J, Camera A, Sikes C. Sertraline treatment for premature ejaculation. J Clin Psychopharmacol 1995;15:341-6.
67. Waldinger MD, Hengeveld MW, Zwinderman AH. Paroxetine treatment of premature ejaculation: a double-blind, randomized, placebo controlled study. Am J Psychiatry 1994;151:1377-9.
68. Kara H, Aydin S, Agargun MY, Odabas O, Yilmaz Y. The efficacy of fluoxetine in the treatment of premature ejaculation: a double-blind placebo controlled study. J Urol 1996;156:1631-2.
69. Spector IP, Carey MP. Incidence and prevalence of sexual dysfunctions: a critical review of the empirical literature. Arch Sex Behav 1990;19:389-408.
70. Shahar E, Lederer J, Herz MJ. The use of a self-report questionnaire to assess the frequency of sexual dysfunction in family practice clinics. Fam Pract 1991;8:206-12.
71. Assalian P. Clomipramine in the treatment of premature ejaculation. J Sex Res 1988;24:213-5.
72. Eaton H. Clomipramine (Anafranil) in the treatment of premature ejaculation. J Int Med Res 1973;18:701.
73. Greist J, Chouinard G, DuBoff E, Halaris A, Kim SW, Koran L, Liebowitz M, Lydiard B, Rasmussen S, White K, Sikes C. Double-blind parallel comparison of three dosages of sertraline in outpatients with obsessive-compulsive disorder. Arch Gen Psychiatry 1995;52:289-95.
74. Klug B. Clomipramine in premature ejaculation [letter]. Med J Aust 1984;141:71.
75. Forster P, King J. Fluoxetine for premature ejaculation [letter]. Am J Psychiatry 1994;151:1523.
76. Graziottin A. Prozac in the treatment of premature ejaculation. Psychopharmacology 1995;153:474A.
77. Kaplan PM. The use of serotonergic uptake inhibitors in the treatment of premature ejaculation. J Sex Marital Ther 1994; 20:321-4.
78. Stratta P, Mancini F, Cupillari M, Rossi A, Cassachia M. Fluoxetine in premature ejaculation [abstract]. J Urol 1993;151:345A.
79. Lee HS, Song DH, Kim C-H, Cho HK. An open clinical trial of fluoxetine in the treatment of premature ejaculation. J Clin Psychopharmacol 1996;16:379-82.
80. Kindler S, Dolberg OT, Cohen H, Hirschmann S, Kotler M. The treatment of comorbid premature ejaculation and panic disorder with fluoxetine. Clin Neuropharmacol 1997;20:466-71.
81. MacHale S, Phanjoo AL. SSRIs to treat sexual dysfunction [letter]. Br J Psychiatry 1994;164:854.
82. Ludovico GM, Corvasce A, Pagliarulo G, Maruco C, Marano A, Pagliarulo A. Paroxetine in the treatment of premature ejaculation. Br J Urol 1996;77:881-2.
83. Swartz DA. Sertraline hydrochloride for premature ejaculation [abstract]. J Urol 1994;151[suppl]:345A.
84. Wise TN. Sertraline as a treatment for premature ejaculation [letter]. J Clin Psychiatry 1994;55:417.
85. Paick J-S, Kim SW. Self therapy with sertraline given prn at 5 pm in treatment of premature ejaculation. J Urol 1998;159[suppl]:241.
86. Waldinger MD, Hengeveld MW, Zwinderman AH. Ejaculation-retarding properties of paroxetine in patients with primary premature ejaculation: a double-blind randomized, dose-response study. Br J Urol 1997;79:592-5.
87. Waldinger MD, Hengeveld MW, Zwinderman AH, Olivier B. Effect of SSRI antidepressants on ejaculation: a double-blind, randomized, placebo-controlled study with fluoxetine, fluvoxamine, paroxetine, and sertraline. J Clin Psychopharmacol 1998;18: 274-81.
88. Florante J, Leyson J. Comparative study between 5 psychotropic drugs in the treatment of premature ejaculation. J Urol 1998; 159[suppl]:241.
89. NIH Consensus Development Panel on Impotence. Impotence NIH Consensus Conference. JAMA 1993;270:83-90.
90. Feldman HA, Goldstein I, Hatzichristou G, Krane RJ, McKinlay JB. Impotence and its medical and psychosocial correlates: results of the Massachusetts male aging study. J Urol 1994;151: 54-61.
91. Araujo AB, Durante R, Feldman HA, Goldstein I, McKinlay JB. The relationship between depressive symptoms and male erectile dysfunction: cross-sectional results from the Massachusetts Male Aging Study. Psychosom Med 1998;60:458-65.
92. Hawton K. The behavioral treatment of sexual dysfunction. Br J Psychiatry 1982;140:94-101.
93. Rosen RC, Leiblum SR, eds. Erectile disorders: assessment and treatment. New York: Guilford Press, 1992.
94. Medical economics data. In: Physician's desk reference. 51st ed. Montvale, NJ: Medical Economics Data Production Co., 1997.
95. Dorevitch A, Davis H. Fluvoxamine-associated sexual dysfunction. Ann Pharmacother 1994;28:872-4.
96. Nemeroff CB, Ninan PT, Ballenger JC, Lydiard RB, Feighner J, Greist JH, Patterson WM. Comparison of the safety and tolerance of fluvoxamine and sertraline in depressed outpatients [abstract]. Eur Neuropsychopharmacol 1995;5:304.
97. Haensel SM, Klem TMAL, Wim CJH, Slob AKS. Fluoxetine and premature ejaculation: a double-blind, crossover, placebo-controlled study. J Clin Psychopharmacol 1998;18:72-7.
98. Labbate LA, Grimes J, Hines A, Oleshansky MA, Arana GW. Sexual dysfunction induced by selective serotonin reuptake antidepressants. J Sex Marital Ther 1998;24:3-12.
99. Mathew RJ, Weinman ML. Sexual dysfunctions in depression. Arch Sex Behav 1982;11:323-5.
100. Kline MD. Fluoxetine and anorgasmia. Am J Psychiatry 1989; 146:804-5.
101. Musher JS. Anorgasmia with the use of fluoxetine [letter]. Am J Psychiatry 1990;147:948.
102. Lydiard RB, George MS. Fluoxetine-related anorgasmy. South Med J 1989;82:933-4.
103. Riley AJ, Riley EJ. Evaluation of drug effects on human sexual dysfunction. In: Riley AJ, Peet M, Wilson C, eds. Sexual pharmacology. Oxford: Clarendon Press, 1993:114-29.
104. Ekselius L, von Knorring L, Eberhard G. A double-blind study comparing sertraline and citalopram in patients with major depression treated in general practice. Eur Neuropsychopharmacology 1997;7[suppl 2]:S147.
105. Ayd FJ. Psychotropic drugs and female sexual dysfunction. Int Drug Ther Newslett 1982;17:37-9.
106. Fisher S, Bryant SG, Kent TA. Post-marketing surveillance by patient self-monitoring: trazodone versus fluoxetine. J Clin Psychopharmacol 1993;13:235-42.
107. Mackay F, Dunn N, Wilton L, Pearce G, Freemantle S, Mann RD. A comparison of fluvoxamine, fluoxetine, sertraline and paroxetine examined by observational cohort studies. Pharmacoepidemiol Drug Saf 1997;6:235-46.
108. Price JS, Waller P, Wood S. Comparison of the post marketing safety of four selective serotonin re-uptake inhibitors including the investigation of symptoms occurring on withdrawal. Br J Clin Pharmacol 1996;42:757-63.
109. Modell JG, Katholi CR, Modell JD, DePalma LR. Comparative sexual side effects of bupropion, fluoxetine, paroxetine and sertraline. Pharmacoepidemiol Drug Util 1997;61:476-87.
110. Preskorn SH, Lane RM. Sertraline 50 mg daily - the optimal daily dose in depression. Int Clin Psychopharmacol 1995;10: 129-41.
111. Feighner J, Overo K, Fieve R, Carman J, Cunningham L, Schwartz G. Fixed dose comparison of citalopram versus placebo in the treatment of outpatients with moderate to severe depression. Presented at the 37th annual meeting of the New Clinical Drug Evaluation Unit, Boca Raton, FL, 1997.
112. Wernicke JF, Dunlop SR, Dornseif BE, Zerbe RL. Fixed-dose fluoxetine therapy for depression. Psychopharmacol Bull 1987; 23:164-8.
113. Tollefson GD, Rampey AH Jr, Potvin JH, Jenike MA, Rush AJ, Kominguez RA, Koran LM, Shear MK, Goodman W, Genduso LA. A multicenter investigation of fixed dose fluoxetine in the treatment of obsessive-compulsive disorder. Arch Gen Psychiatry 1994;51:559-67.
114. Walczak DD, Apter JT, Halikas JA, Borison RL, Carman JS, Post GL, Patrick R, Cohn JB, Cunningham LA, Rittberg B, Preskorn SH, Kang JS, Wilcox CS. The oral dose-effect relationship for fluvoxamine: a fixed-dose comparison against placebo in depressed outpatients. Ann Clin Psychiatry 1996;8:139-51.
115. Dunner DL, Dunbar GC. Optimal dose regimen for paroxetine. J Clin Psychiatry 1992;53[suppl 2]:21-6.
116. Wheadon DE, Bushnell WD, Steiner M. A fixed dose comparison of 20, 40, or 60 mg paroxetine to placebo in the treatment of obsessive-compulsive disorder [abstract]. Presented at the American Congress of Neuropharmacology, Honolulu, HI, 1993.
117. Ballenger JC, Wheadon DE, Steiner M, Bushnell W, Gergel IP. Double-bund, fixed dose, placebo-controlled study of paroxetine in the treatment of panic disorder. Am J Psychiatry 1998; 155:36-42.
118. Londborg PD, Wolkow R, Smith WT, DuBoff E, England D, Ferguson J, Rosenthal M, Weise C. Sertraline in the treatment of panic disorder: a multisite, double-blind, placebo-controlled fixed dose investigation. Br J Psychiatry 1998;173:54-60.
119. Fabre LF, Abuzzahab FS, Amin M, Claghorn JL, Mendels J, Petrie WM, Dube S, Small JG. Sertraline safety and efficacy in major depression: a double-blind fixed-dose comparison with placebo. Biol Psychiatry 1995;38:592-602.
120. Ashton AK, Hamer R, Rosen RC. Serotonin reuptake inhibitor-induced sexual dysfunction and its treatment: a large-scale retrospective study of 596 psychiatric outpatients. J Sex Marital Ther 1997;23:165-75.
121. Agren H, Aberg-Wistedt A, Akerblad A-C. Sertraline vs. paroxetine in major depression: a multicenter, double-blind, 24-week comparison [NR366]. New Research Abstracts from the American Psychiatric Association Annual Meeting, Toronto, Canada, May 30 to June 4, 1998.
122. Linggjaerde O, Ahlfors UG, Bech P, Dencker SJ, Elgen K. The UKU-side effect rating scale. Acta Psychiatr Scand 1987; 76[suppl 334]:1-100.
123. Kiev A, Feiger A. A double-blind comparison of fluvoxamine and paroxetine in the treatment of depressed outpatients. J Clin Psychiatry 1997;58:146-52.
124. Feiger A, Kiev A, Shrivastava RK, Wisselink PG, Wilcox CS. Nefazodone versus sertraline in outpatients with major depression: focus on efficacy, tolerability, and effects on sexual function and satisfaction. J Clin Psychiatry 1996;57[suppl 2]:53-62.
125. Kavoussi RJ, Segraves RT, Hughes AR, Ascher JA, Johnston JA. Double-blind comparison of bupropion sustained release and sertraline in depressed outpatients. J Clin Psychiatry 1997;58: 532-7.
126. Bennie EH, Mullin JM, Martindale JJ. A double-blind multicenter trial comparing sertraline and fluoxetine in outpatients with major depression. J Clin Psychiatry 1995;56:229-37.
127. Van Moffaert M, Bartholome F, Cosyns P, De Nayer AR, Mertens C. A controlled comparison of sertraline and fluoxetine in acute and continuation treatment of major depression. Hum Psychopharmacol 1995;10:393-405.
128. Linden RD, Newhouse P, Krishnan KR, Farmer M, Goldstein BJ, Lazarus LW. SSRIs in the depressed elderly: a double-blind comparison of sertraline and fluoxetine in depressed geriatric outpatients. Poster presented at the 148th Meeting of the American Psychiatric Association, Miami, FL, May 20-25, 1995.
129. Latimer PR, Ravindran AV, Bernatchez J-P, Fournier J-P, Gojer JA, Barrat K, Buttars J. A six month comparison of toleration and efficacy of sertraline and fluoxetine treatment of major depression. Eur Neuropsychopharmacol 1996;6[suppl 3]:124.
130. Bitran D, Hull EM. Pharmacological analysis of male rat sexual behavior. Neurosci Biobehav Rev 1988;11:365-89.
131. 1B receptors. Pharmacol Biochem Behav 1992;42:529-33.
132. 2 receptor in the regulation of sexual performance in male rats. Life Sci 1989;45:1263-70.
133. IC/ID receptor agonists produce reciprocal effects on male behavior of rhesus monkeys. Eur J Pharmacol 1993;243:227-34.
134. Baldessarini RJ, Marsh E. Fluoxetine and side effects. Arch Gen Psychiatry 1990;47:191-2.
135. Pollack MH, Reiter S, Hammerness P. Genitourinary and sexual adverse effects of psychotropic medication. Int J Psychiatry Med 1992;22:305-27.
136. Mendelson S. A review and reevaluation of the role of serotonin in the modulation of lordosis behavior in the female rat. Neurosci Biobehav Rev 1991;16:309-50.
137. 3 antagonist granisetron. J Clin Psychiatry 1997;58:11:496-7.
138. Hyttel J. Comparative pharmacology of selective serotonin reuptake inhibitors (SSRIs). Nordic J Psychiatry 1993;47[suppl 30]:5-20.
139. Bolden-Watson C, Richelson E. Blockade by newly developed antidepressants of biogenic amine uptake into rat brain synaptosomes. Life Sci 1993;52:1023-9.
140. Tatsumi M, Groshan K, Blakely RD, Richelson E. Pharmacological profile of antidepressants and related compounds at human monoamine transporters. Eur J Pharmacol 1997;340:249-58.
141. Segraves RT. Effects of psychotropic drugs on human erection and ejaculation. Arch Gen Psychiatry 1989;46:275-84.
142. Sullivan G, Lukoff D. Sexual side effects of antipsychotic medication: evaluation and interventions. Hosp Community Psychiatry 1990;41:1238-41.
143. Barbeau A. l-dopa therapy in Parkinson's disease: a critical review of nine years' experience. Can Med Assoc J 1969;101: 59-68.
144. O'Brien CP, DiGiacomo JN, Fahn S, Schwarz GA. Mental effects of high-dosage levodopa. Arch Gen Psychiatry 1971;24:61-4.
145. Balogh S, Hendricks SE, Kang J. Treatment of fluoxetine-induced anorgasmia with amantadine [letter]. J Clin Psychiatry 1992;53:212-3.
146. Gitlin MJ. Treatment of sexual side effects with dopaminergic agents [letter]. J Clin Psychiatry 1995;56:124.
147. Bartlick BD, Kaplan PM, Kocsis JH. The effects of antidepressants on sexuality [comment]. Primary Psychiatry 1995;2:13.
148. Leyman S, Mattelaer PM, Van Steenberge I, Schotte G. Paroxetine post marketing experience on 4042 depressed patients in Belgium. Eur J Clin Res 1995;7:287-96.
149. Meltzer HY, Young M, Metz J, Fang VS, Schyve PM, Arora RC. Extrapyramidal side effects and increased serum prolactin following fluoxetine, a new antidepressant. J Neural Transm 1979; 45:165-75.
150. Bouchard RH, Pourcher E, Vincent P. Fluoxetine and extrapyramidal side effects. Am J Psychiatry 1989;146:1352-3.
151. Lal S, Ackman D, Thavundayil JX, Kiely ME, Etienne PC. Effect of apomorphine, a dopamine receptor agonist, on penile tumescence in normal subjects. Prog Neuropsychopharmacol Biol Psychiatry 1984;8:695-9.
152. Danjou P, Alexandre L, Warot K, Lacomblez L, Puech AJ. Assessment of erectogenic properties of apomorphine and yohimbine in man. Br J Clin Pharmacol 1988;26:733-9.
153. Cohen MA, Davies PH. Drug therapy and hyperprolactinemia. Adverse Drug React Bull 1998;190:723-6.
154. Crenshaw TL, Goldberg JP, eds. Sexual pharmacology: drugs that affect sexual functioning. New York: W.W. Norton & Company, 1996:369-408.
155. Zohar J, Insel TR, Zohar-Kadouch RC, Hill JL, Murphy DL. Serotonergic responsivity in obsessive-compulsive disorder effects of chronic clomipramine treatment. Arch Gen Psychiatry 1988; 45:167-72.
156. Price LH, Charney DS, Delgado PL, Anderson GM, Heninger GR. Effects of desipramine and fluvoxamine treatment on the prolactin response to tryptophan: serotonergic function and the mechanism of antidepressant action. Arch Gen Psychiatry 1989; 46:625-31.
157. Wing Y-K, Clifford EM, Sheehan BD, Campling GM, Hockney RA, Cowen PJ. Paroxetine treatment and the prolactin response to sumatriptan. Psychopharmacology (Berl) 1996;124:377-9.
158. Anand VS. Clomipramine-induced galactorrhea and amenorrhea. Br J Psychiatry 1985;147:87-8.
159. Mills IH. Endocrine responses to psychotropic drugs. Br J Clin Pract 1979;61[suppl 4];61-4.
160. Fowlie S, Burton J. Hyperprolactinemia and nonpuerperal l-actation associated with clomipramine. Scott Med J 1987; 32:52.
161. Cowen PJ, Sargent PA. Changes in plasma prolactin during SSRI treatment: evidence for a delayed increase in 5-HT neurotransmission. J Psychopharmacol 1997;4:345-8.
162. Amsterdam JD, Garcia-Espana F, Goodman D, Hooper M, Hornig-Rohan M. Breast enlargement during chronic antidepressant therapy. J Affect Disord 1998;46:151-6.
163. Michael A, Herrod JJ. Citalopram-induced decreased libido [letter]. Br J Psychiatry 1997;171:90.
164. Naranjo CA, Sellers EM, Sullivan JT, Woodley DV, Kadlec K, Sykora K. The serotonin uptake inhibitor citalopram attenuates ethanol intake. Clin Pharmacol Ther 1987;41:266-74.
165. Nyth AL, Gottfries CG. The clinical efficacy of citalopram in the treatment of emotional disturbances in dementia disorders: a Nordic multicenter study. Br J Psychiatry 1990;157:894-901.
166. Laine K, Anttila M, Heinonen E, Helminen A, Huupponen R, Maki-Ikola O, Reinikainen K, Scheinin M. Lack of adverse interactions between concomitantly administered selegiline and citalopram. Clin Neuropharmacol 1997;20:419-33.
167. Gordon C, Whale R, Cowen PJ. Sertraline treatment does not increase plasma prolactin levels in healthy subjects. Psychopharmacology (Berl) 1998;137:201-2.
168. Goodnick PJ, Goldstein BJ. Selective serotonin reuptake inhibitors in affective disorders: I. Basic pharmacology. J Psychopharmacol 1998;12[suppl]:5.
169. Bronzo MR, Stahl SM. Galactorrhea induced by sertraline [letter]. Am J Psychiatry 1993;150:1269-70.
170. Hall MJ. Breast tenderness and enlargement induced by sertraline [letter]. Am J Psychiatry 1994;129:738.
171. Richelson E. The pharmacology of antidepressants at the synapse: focus on newer compounds. J Clin Psychiatry 1994; 55[suppl A]:34-9.
172. Stanton T, Bolden-Watson C, Cusack B, Richelson E. Antagonism of the five cloned human muscarinic cholinergic receptors expressed in CHO-K1 cells by antidepressants and antihistaminics. Biochem Pharmacol 1993;45:2352-4.
173. Pollack BG, Mulsant BH, Nebes R, Kirshner MA, Begley AE, Reynolds CF. Serum anticholinergicity in older patients treated with paroxetine or nortriptyline. Am J Psychiatry 1998;155: 1110-2.
174. Robbe HWJ, O'Hanlon JF. Acute and subchronic effects of paroxetine 20 and 40 mg on actual driving, psychomotor performance, and subjective assessments in healthy volunteers. Eur Neuropsychopharmacol 1995;5:35-42.
175. Geretsegger C, Bohmer F, Ludwig M. Paroxetine in the elderly depressed patient: randomized comparison with fluoxetine of efficacy, cognitive and behavioural effects. Int Clin Psychopharmacol 1994;9:25-9.
176. Lewis CF, De Quardo JR, DuBose C, Tandon R. Acute angle-closure glaucoma and paroxetine. J Clin Psychiatry 1997;58:123-4.
177. Eke T, Bates AK. Acute angle closure glaucoma associated with paroxetine. BMJ 1997;314:1387.
178. Raptopoulos P, McClelland GR, Jackson D. The clinical pharmacology of paroxetine in healthy subjects. Extended abstracts and poster presentations of the Paroxetine Symposium, Rome, 1998.
179. Deijen JB, Loriaux SM, Orlebeke JF, de Vries J. Effects of paroxetine and maprotiline on mood, perceptual-motor skills and eye movements in healthy volunteers. J Psychopharmacol 1989; 3:149-55.
180. Kerr JS, Fairweather DB, Mahendren R, Hindmarch I. The effects of paroxetine, alone and in combination with alcohol on psychomotor performance and cognitive function in the elderly. Int Clin Psychopharmacol 1992;7:101-8.
181. Hindmarch I, Harrison C. The effects of paroxetine and other antidepressants in combination with alcohol on psychomotor activity related to car driving. Hum Psychopharmacol 1988;3:13-20.
182. Adaikan PG, Karim SMM, Kottegoda SR, Ratnam SS. Cholinoreceptors in the corpus cavernosum muscle of the human penis. J Auton Pharmacol 1983;3:107-11.
183. Klinge E, Sjostrand NO. Comparative study of some isolated mammalian smooth muscle effectors of penile erection. Acta Physiol Scand 1977;100:354-67.
184. Smirai M, Sadaki K, Rikimaru A. Biochemical investigation on the distribution of adrenergic and cholinergic nerves in human penis. Tohoku J Exp Med 1972;104:403-4.
185. Benson GS, McConnell J, Lipshultz LI, Corriere JN, Wood J. Neuromorphology and neuropharmacology of the human penis. J Clin Invest 1980;65:506-12.
186. McConnell J, Benson GS, Wood J. Autonomic innervation of the mammalian penis: a histochemical and physiological study. J Neural Transm 1979;45:227-38.
187. Finkel MS, Laghrissi-Thode F, Pollock BG, Rong J. Paroxetine is a novel nitric oxide synthetase inhibitor. Psychopharmacol Bull 1996;32:653-8.
188. Stahl SM. How psychiatrists can build new therapies for impotence. J Clin Psychiatry 1988;59:47-8.
189. Bredt DS, Hwang PH, Glatt C, Lowenstein C, Reed RR, Snyder S. Cloned and expressed nitric oxide synthetase structurally resembles cytochrome P450 reductase. Nature 1991;351:714-8.
190. Renodon A, Boucher JL, Sari MA, Delaforge M, Mansy D. Bromocriptine is a strong inhibitor of brain nitric oxide synthetase: possible consequences for the origin of its therapeutic effects. FEBS Lett 1997;406:33-6.
191. Patterson WM. Fluoxetine-induced sexual dysfunction [letter]. J Clin Psychiatry 1993;54:71.
192. Hsu JH, Shen WW. Male sexual side effects associated with antidepressants: a descriptive clinical study of 32 patients. Int J Psychiatry Med 1995;25:191-201.
193. Bennazi F, Mazzoli M. Fluoxetine-induced sexual dysfunction: a dose-dependent effect? Pharmacopsychiatry 1994;27:246.
194. Olivera AA. Sexual dysfunction due to clomipramine and sertraline: non-pharmacological resolution. J Sex Educ Ther 1994; 20:119-22.
195. Walker PW, Cole JO, Gardner EA, Hughes AR, Johnston JA, Batey SR, Lineberry CG. Improvement in fluoxetine-associated sexual dysfunction in patients switched to bupropion. J Clin Psychiatry 1993;54:459-65.
196. Ashton AK, Rosen RC. Bupropion as an antidote for serotonin reuptake inhibitor-induced sexual dysfunction. J Clin Psychiatry 1998;59:112-5.
197. Rosen RC, Ashton AK. Prosexual drugs: empirical status of the "new aphrodisiacs." Arch Sex Behav 1993;22:521-44.
198. Balogh S, Hendricks S. Titration of serotonin reuptake blockers. J Clin Psychiatry 1993;54:115.
199. Pollock BG, Sweet RA, Kirshner M, Reynolds CF III. Bupropion plasma levels and CYP2D6 phenotype. Ther Drug Monit 1996; 18:581-5.
200. 2a/ac and D2 antagonist, in the treatment of sexual dysfunction induced by serotonin reuptake inhibitors. Clin Neuropharmacol 1997;20:210-4.
201. Cohen AJ, Bartlick BD. Ginkgo biloba for antidepressant-induced sexual dysfunction. J Sex Marital Ther 1998;24:139-43.
202. Feder R. Reversal of antidepressant activity of fluoxetine by cyproheptadine in three patients. J Clin Psychiatry 1991;52:163-4.
203. Goldbloom DS, Kennedy SH. Adverse interaction of fluoxetine and cyproheptadine in two patients with bulimia nervosa. J Clin Psychiatry 1991;52:261-2.
204. McCormick S, Olin J, Brotman AW. Reversal of fluoxetine-induced
205. Aizenberg D, Zemishlany Z, Weizman A. Cyproheptadine treatment of sexual dysfunction induced by serotonin reuptake inhibitors. Clin Neuropharmacol 1995;18:320-4.
206. Lauerma H. Successful treatment of citalopram-induced anorgasmia by cyproheptadine. Acta Psychiatr Scand 1996;93:69-70.
207. Hollander E, McCarley A. Yohimbine treatment of sexual side effects induced by serotonin reuptake blockers. J Clin Psychiatry 1992;53:207-9.
208. Segraves RT. Treatment of drug-induced anorgasmia [letter]. Br J Psychiatry 1994;165:554.
209. Norden MJ. Buspirone treatment of sexual dysfunction associated with selective serotonin re-uptake inhibitors. Depression 1994;2:109-12.
210. Landen MSG, Eriksson E, Agren H, Fahlen T. Buspirone provides relief for sexual side effects induced by SSRIs [NR694]. New Research Abstracts from the American Psychiatric Association Annual Meeting, Toronto, Canada, May 30 to June 4, 1998.
211. Reynolds RD. Sertraline-induced anorgasmia treated with intermittent nefazodone [letter]. J Clin Psychiatry 1997;58:89.
212. Fava M, Rankin MA, Alpert JE, Nierenberg AA, Worthington JJ. An open trial of oral sildenafil in antidepressant-induced sexual dysfunction. Psychosom Psychother (in press).
213. Roeloffs C, Barlick B, Kaplan PM, Kocsis JH. Methylphenidate and SSRI-induced sexual side effects [letter]. J Clin Psychiatry 1996;57:548.
214. Labbate LA, Pollack MH. Treatment of fluoxetine-induced sexual dysfunction with bupropion: a case report Ann Clin Psychiatry 1994;6:13-5.
215. Grimes JB, Labbate LA. Spontaneous orgasm with the combined use of bupropion and sertraline. Biol Psychiatry 1996;40:1184-5.
216. Gardner EA, Johnston JA. Bupropion: an antidepressant without sexual pathophysiological action. J Clin Psychopharmacol 1995; 15:24-9.
217. Shrivastava RK, Shrivastava S, Overweg N, Schmitt M. Amantadine in the treatment of sexual dysfunction associated with selective serotonin reuptake inhibitors. J Clin Psychopharmacol 1995;15:83-4.
218. Balon R. Intermittent amantadine for fluoxetine-induced anorgasmia. J Sex Marital Ther 1996;22:290-2.
219. Massand PS, Reddy N, Gregory R. SSRI-induced sexual dysfunction sucessfully treated with amantadine. Depression 1995; 2:319-21.
220. Ascher JA, Cole JO, Colin J-N, Feighner JP, Ferris RM, Fibiger HC, Golden RN, Martin P, Potter WZ, Richelson E, et al. Bupropion: a review of its mechanism of antidepressant activity. J Clin Psychiatry 1995;56:395-401.
221. Bodkin JA, Lasser RA, Wines JD, Gardner DM, Baldessarini RJ. Combining serotonin reuptake inhibitors and bupropion in partial responders to antidepressant monotherapy. J Clin Psychiatry 1997;58:137-45.
222. Van Putten T, Shaffer I. Delirium associated with bupropion [letter]. J Clin Psychopharmacol 1990;10:234.
223. Preskorn SH. Should bupropion dosage be adjusted based on therapeutic drug monitoring? Psychopharmacol Bull 1991;27: 637-43.
224. Zubieta JK, Demitrack MA. Possible bupropion precipitation of mania and a mixed affective state. J Clin Psychopharmacol 1991;11:327-8.
225. Gerner RH, Kaufman KR, Rosen R. Seizures associated with bupropion and SSRI co-therapy [abstract]. Biol Psychiatry 1998;43:99S.
226. Lane R. Pharmacokinetic drug interaction potential of serotonin reuptake inhibitors. Int Clin Psychopharmacol 1996;11[suppl 5]:31-61.
227. Ereshefsky L. Drug-drug interactions involving antidepressants: focus on venlafaxine. J Clin Psychopharmacol 1996;16[suppl 2]:37S-53S.
228. Stoll AL, Pillay SS, Diamond L, Workum SB, Cole JO. Methylphenidate augmentation of serotonin selective reuptake inhibitors: a case series. J Clin Psychiatry 1996;57:72-6.
229. Ahlenius S, Larsson K, Svensson L, Hjorth S, Carlsson A, Lindberg P, Wikstrom H, Sanchez D, Arvidsson L, Hacksell U, Nilsson JLG. Effects of a new type of 5-HT receptor agonist on male rat sexual behavior. Pharmacol Biochem Behav 1981;15:758-92.
230. Tome MB, Isaac M. Effects of augmenting agents on prolactin and cortisol in resistant depression. Poster presented at the 36th Annual Meeting of the American College of Neuropsychopharmacology, Hawaii, December 8-12, 1997.
231. Gelenberg AJ, Bassuk EL, Schoonover SC. The practitioner's guide to psychoactive drugs. 3rd ed. New York, Plenum, 1991: 1997.
232. Preskorn SH. Do you believe in magic? J Pract Psychiatry Behav Health 1997;6:99-103.
233. Robillard M, Lieff S. Augmentation of antidepressant therapy by buspirone: three geriatric case histories. Can J Psychiatry 1995; 40:639-40.
234. Grady TA, Pigott TA, L'Heureux F, Murphy DL. Seizure associated with fluoxetine and adjuvant buspirone therapy. J Clin Psychopharmacol 1992;12:70-1.
235. Lebert F, Pasquier F, Goudemand M, Petit H. Euphoria with buspirone after fluoxetine treatment [letter]. Am J Psychiatry 1993; 150:167.
236. Jacobsen FM. Possible augmentation of antidepressant response by buspirone. J Clin Psychiatry 1991;525:217-20.
237. Joffe RT, Schuller DR. An open study of buspirone augmentation of serotonin reuptake inhibitors in refractory depression. J Clin Psychiatry 1993;54:269-71.
238. Fahlen T, Agren H, Edstom A, Rooth K. Buspirone augmentation of SSRI therapy in treatment refractory depression [abstract]. Eur Neuropsychopharmacol 1996;6[suppl 3]:127.
239. Menkes DB. Buspirone augmentation of sertraline. Br J Psychiatry 1995;166:823-4.
240. Arnott S, Nutt D. Successful treatment of fluvoxamine-induced anorgasmia by cyproheptadine. Br J Psychiatry 1994;164:838-9.
241. Hollander E, Mullen LS, Carrasco JL, DeCaria CM, Stein DJ. Symptom relapse in bulimia nervosa and obsessive compulsive disorders after treatment with serotonin antagonists [letter]. J Clin Psychiatry 1992;53:28.
242. Katz RJ, Rosenthal M. Adverse interaction of cyproheptadine with serotonergic antidepressants [letter]. J Clin Psychiatry 1994;55:314-5.
243. Christensen RC. Adverse interaction of paroxetine and cyproheptadine [letter]. J Clin Psychiatry 1995;56:433-4.
244. Kowalski A, Stanley RO, Dennerstein L, Burrows G, Maguire KP. The sexual side-effects of antidepressant medication: a double-blind comparison of two antidepressants in a non-psychiatric population. Br J Psychiatry 1985;147:413-8.
245. Gelenberg AJ, Laukes C, McGahey, Okayli G, Moreno F, Bologna L, Delgado P. Mirtazapine substitution in SSRI-induced sexual dysfunction. Poster presented at the 36th annual meeting of the American College of Neuropsychopharmacology, Hawaii, December 8-12, 1997.
246. Koutouvidis N, Pratikakis M, Fotiadou A, Istikoglou C. The use of mirtazapine in a group of 11 patients following poor compliance to SSRI treatment due to sexual dysfunction[abstract]. Eur Neuropsychopharmacol 1997;7[suppl 2]:S156.
247. Marino MR, Langenbacher M, Ulderman HD. Interaction of nefazodone and fluoxetine [abstract]. Clin Pharmacol Ther 1996;59:180.
248. Bennazi F. Dangerous interaction with nefazodone added to fluoxetine, desipramine, venlafaxine, valproate and clonazepam combination therapy. J Psychopharmacol 1997;2:190-1.
249. Castaneda R, Levy R, Westreich LM, Sussman N. Drug craving and other negative reactions after abrupt substitution of nefazodone for other serotonergic agents. J Clin Psychiatry 1996; 57:485-6.
250. Rothschild AJ. Selective serotonin reuptake inhibitor-induced sexual dysfunction: efficacy of a drug holiday. Am J Psychiatry 1995;152:1514-6.
251. Fava ML. A comparison of symptoms following treatment interruption: evidence from a randomized double-blind trial with fluoxetine, sertraline and paroxetine. Poster presented at the first CINP Congress, Glasgow, Scotland, July 12-16, 1998.
252. Lane RM. Withdrawal symptoms after discontinuation of selective serotonin reuptake inhibitors (SSRIs). J Serotonin Res 1996;3:75-83.
253. Coupland MJ, Bell CJ, Potokar JP. Serotonin reuptake inhibitor withdrawal. J Clin Psychopharmacol 1996;16:356-62.
254. Nemeth A, Arato M, Treuer T, Vandlik E. Treatment of fluvoxamine-induced anorgasmia with a partial drug holiday [letter]. Am J Psychiatry 1996;153:1365.
255. Weiner DN, Rosen RC. Medications and their impact on sexual function. In: Sipski ML, Alexander CJ, eds. Sexual function in people with disability and chronic illness. Gaithersburg, MD: Aspen Publishers, 1997:85-118.